This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Richter Gedeon Nyrt.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Zsolt Némethy: Innovator in Pharmaceutical Chemistry
Introduction
Zsolt Némethy is a notable inventor based in Göd, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on thiadiazine derivatives. His research focuses on the development of compounds that can modulate the activity of nicotinic acetylcholine receptors, which are crucial for various biological functions.
Latest Patents
Zsolt Némethy holds 1 patent for his invention related to thiadiazine derivatives. This patent encompasses not only the derivatives themselves but also their pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates, and hydrates. The pharmaceutical compositions derived from these compounds are designed for use as modulators of α7 nicotinic acetylcholine receptor activity in mammalian subjects.
Career Highlights
Zsolt Némethy is associated with Richter Gedeon Nyrt., a prominent pharmaceutical company in Hungary. His work at this institution has allowed him to contribute to the advancement of drug development and therapeutic solutions. His expertise in pharmaceutical chemistry has positioned him as a valuable asset in the field.
Collaborations
Throughout his career, Zsolt has collaborated with esteemed colleagues such as István Ledneczki and János Éles. These collaborations have fostered a productive environment for innovation and research in pharmaceutical sciences.
Conclusion
Zsolt Némethy is a distinguished inventor whose work on thiadiazine derivatives has the potential to impact the pharmaceutical industry significantly. His contributions reflect a commitment to advancing medical science and improving therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
